Skip to main content
SpringerLink
Log in

Pharmacokinetics and metabolism of vincamine and related compounds

  • Review Paper
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics and metabolism of vincamine, vinpocetine, methylene-methoxy-apovincaminic acid ester and eburnamine have been reviewed. The main route of elimination for vincamine, vinpocetine and methylene-methoxy-apovincaminic acid ester is ester cleavage and conjugation in the case of eburnamine. Vincamine and its derivatives show significant differences in metabolic pathway and their elimination is rapid in the species studied. Emphasis has been placed on the analytical methods used for monitoring these drugs in biological systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zabolotnaya E.S. (1950): Study of Vinca minor L. (in Russian) Trudy vsesoyuznogo nauchno-issledovatelnogo instituta lekatstvennych rastenij (Moscow),10, 29–33.

    Google Scholar 

  2. Schlittler E. and Furlenmejer A. (1953): Vincamin, ein Alkaloid aus Vinca minor L. (Apocynaceae). Helv. Chim. Acta,36, 2017–2020.

    Article  CAS  Google Scholar 

  3. Trojánek J., Štrouf O., Holubeck J. and Čekan Z. (1961): Structure of vincamine, Tetrahedron Letters,20, 702–706.

    Article  Google Scholar 

  4. Raymond-Hamet (1954): Sur quelques propriétés physiologiques de la vincamine, alcaloïde cristallisé de la petite pervenche (Vinca minor L.). Compt. Rend. Soc. Biol.,148, 1082–1086.

    CAS  Google Scholar 

  5. Quevauviller A., Le Men J. and Janot M.M. (1955): Ann. Pharmacol. Fr.,13, 328.

    CAS  Google Scholar 

  6. Szász K., Szporny L., Bittner E., Gyenes I., Havel E. and Margó I. (1958): On the crystallized alkaloid of Vinca minor L. (in Hungarian). Magyar Kémiai Folyóirat,64, 296–297.

    Google Scholar 

  7. Szporny L. and Szász K. (1959): Die pharmakologischen Untersuchungen des Vincamins. Naunyn Schmiedeberg’s Arch. exp. Path. Pharm.,236, 296–298.

    CAS  Google Scholar 

  8. Görög P. and Szporny L. (1961): Effect of Vincamine on the noradrenaline content of rat tissue. Biochem. Pharmacol.,8, 259–262.

    Article  PubMed  Google Scholar 

  9. Görög P. and Szporny L. (1962): The depleting effect of vincamine on the cerebral serotonin level. Biochem. Pharmacol.,11, 165–166.

    Article  PubMed  Google Scholar 

  10. Szabó Z. and Nagy Z. (1960): Tierexperimentelle und klinische Untersuchungen über die blutdrucksenkende Wirkung des Vincamins. Arzneim.-Forsch. (Drug. Res.),10, 811–813.

    Google Scholar 

  11. Wotchal B.E. and Tschapidze G.E. (1965): Das Verhalten der peripheren Gefässe bei der Hypertoniekrankheit. Ther. Hung.,13, (3) 3–6.

    Google Scholar 

  12. Dekoninck W.J., Joquet Ph., Jacquy J. and Henriet M. (1978): Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. Arzneim.-Forsch. (Drug. Res.),28, 1654–1657.

    CAS  Google Scholar 

  13. Depresseux J.C. (1977): The cerebral Hemodynamic effect of vincamine. Acta Neurol. Scand.,64, Suppl. 408–411.

    CAS  Google Scholar 

  14. Földi M., Obal F. and Szeghy G. (1965): Über die Wirkung von Devincan (Vinca minor-Alkaloide) auf das EEG und das Augenhintergrundbild bei Zerebralsklerotikern. Med. Welt,37, 2122–2124.

    PubMed  Google Scholar 

  15. Ravina A. (1966): Une indication thérapeutique nouvelle des alcaloïdes de la pervenche. Press méd.,74, 525–527.

    CAS  PubMed  Google Scholar 

  16. Taylor W.I. and Farnsworth N.R. (eds.) (1973): The Vinca Alkaloids, Mercel Dekker Inc. New York.

    Google Scholar 

  17. Szporny L. (1977): Pharmacologie de la vincamine et de ses dérivés. Actualités pharmacologiques,29, 87–117.

    CAS  PubMed  Google Scholar 

  18. Kuehne M.E. (1964): The total synthesis of vincamine. J. Am. Chem. Soc.,86, 2946.

    Article  CAS  Google Scholar 

  19. Szántay Cs., Szabó L. and Kalaus Gy (1973): Stereoselective total synthesis of (+)-vincamine. Tetrahedron Letters,3, 191–192.

    Article  Google Scholar 

  20. Kárpàati E. and Szporny L. (1976): General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneim.-Forsch. (Drug Res.),26, 1908–1912.

    Google Scholar 

  21. Aurousseau M., Albert O. and Huet Y. (1976): First pharmacological data on an indolic compound active on cerebral blood flow. The (±)epi-21-desethyl eburnamonine. in “Symposium on Pharmacology of Vinca Alkaloids.” (Second Congress of the Hungarian Pharmacological Society, Vol. 5. (Knoll J. and Fekete Gy. eds.). Akadémiai Kiadó, Budapest, p. 5–8.

    Google Scholar 

  22. Aurousseau M., Linee Ph., Albert O. and Lacroix P. (1976): Comparative pharmacology of vincamine and two optical antipodes with indolic structure: d- and 1-eburnamonine. ibid. p. 13–16.

    Google Scholar 

  23. Biró K. and Kárp á ti E. (1976): Protective effect of synthetic vinca alkaloids on ischemic anoxia of the brain. ibid. p. 51–54.

    Google Scholar 

  24. De Angelis L. (1980): Apovincamine. Drug of the Future (Spain),5, 118–119.

    Google Scholar 

  25. Galzigna L., Quadro G. and Saccarello M.L. (1981): Synthesis and some properties of a new vincamine derivative. Eur. J. Med. Chem.,16, 191–192.

    CAS  Google Scholar 

  26. Ezer E. and Szporny L. (1967): The absorption, elimination and distribution of14C-vincamine in the organism (in Hungarian) Kisérl. Orvostud.,19, 67–70.

    CAS  Google Scholar 

  27. Iven H. and Siegers C.-P. (1977): Fluorimetrischer Nachweis und Pharmakokinetik von Vincamin bei Ratten. Arzneim.-Forsch. (Drug. Res.),27, 1248–1254.

    CAS  Google Scholar 

  28. Vereczkey L., Tamás J., Czira G. and Szporny L. (1980): Metabolism of vincamine in the rat in vivo and in vitro. Arzneim.-Forsch. (Drug. Res.),30, 1860–1865.

    CAS  Google Scholar 

  29. Viganó V., Paracchini S., Pesce E. and Piacenza G. (1978): MS identification of the vincamine metabolites. Quantitative mass spectrometry in life sciences II. Proceedings of the second international symposium held at the state university of Ghent (de Leentzer A. P., Roncucci R.R. and von Pethegem C. eds.). Elsevier Sci. Publ. Co. Amsterdam-Oxford-New York, p. 357–366.

    Google Scholar 

  30. Viganó V., Paracchini S., Piacenza G. and Pesce E. (1978): Metabolismo della vincamina nel ratto. II Farmaco (Ed. Sc.),33, 583–594.

    Google Scholar 

  31. Vereczkey L., Tamás J., Czira G., Rosdy B. and Szporny L. (1980): Metabolism of vincamine and some of related compounds. Recent Developments in Mass Spectrometry in Biochemistry and Medicine, Vol. 6. (Frigerio A. and McCamish M. eds.). Elsevier Sci. Publ. Co. Amsterdam, p. 267–282.

    Google Scholar 

  32. Camón L., Rodriguez Farré E. and Valdecassas F.G. (1976): Caracteristicas de la radioactividad en orina tras la administración de vincamina-3H en humanos. Arch. Farmacol. Toxicol. (Spain),2, 304–306.

    Google Scholar 

  33. Vereczkey L. and Szporny L. (1974): Pharmacokinetic studies on vincamine and some of its derivatives. Pharmacology Meeting Graz ’74. Naunyn-Schmiedeberg’s Archives of Pharmacology,285 (Suppl.) R88.

    Google Scholar 

  34. Ventouras K., Schulz P., Doelker E., Boucherat J. and Buri P. (1976): Étude pharmacocinétique de la vincamine administrée par voie orale. Pharm. Acta Helv.,51, 334–342.

    CAS  PubMed  Google Scholar 

  35. Camón M.L., Rodriguez Farré E. and Valdecasas F.G. (1975): Pharmacokinetic study of vincamine-3H in man. 6th Int. Congr. Pharmacol. Helsinki, Abs. No. 155.

  36. Camón L., Rodriguez Farré E. and Valdecasas F.G. (1978): Comportamiento cinético de la vincamina-3H en homanos, Análisis compartimental. Arch. Farmacol. Toxicol. (Spain),4, 39–40.

    Google Scholar 

  37. Ventouras K., Balant L., Revillard C. and Buri P. (1977): Application de l’analyse multicompartimentale à la Pharmacocinétique de la vincamine chez l’homme. Pharm. Acta Helv.,52, 97–105.

    CAS  PubMed  Google Scholar 

  38. Viganó V., Rognoni F., Piacenza G. and Pesce E. (1978): Assorbimento, distribuzione ed eliminazione della vincamina cloridrato nel ratto. Il Farmaco (Ed. Pr.),33, 224–231.

    Google Scholar 

  39. Bressole F., Bres J. and Brun S. (1979): Dosage des médicaments par spectrophotométrie in situ des chromatogrammes en vue de leur étude pharmacocinétique. I. Sulpiride et autres benzamides, vincamine, naftazone. J. Chromatog.,174, 421–433.

    Article  Google Scholar 

  40. Laufen H., Juhran W., Fleissig W., Götz R., Scharpf F. and Bartsch G. (1977): Zur Pharmacokinetic von Vincamine nach intravenöser un oraler Verabreichung am Hund. Arzneim.-Forsch. (Drug. Res.),27, 1255–1264.

    CAS  Google Scholar 

  41. Klnsun H. and Moulin M.A. (1977): Gas chromatographic method for the determination of vincamine in blood. J. Chromatog.,144, 123–126.

    Article  Google Scholar 

  42. Lücker P.W., Simon B. and Talmot D.M. (1978): Zur Pharmacokinetic eines Vincamin-Mehrschitdragées: Versuch an gesunden Probanden. Arzneim.-Forsch. (Drug Res.),28, 79–82.

    Google Scholar 

  43. Devaux P., Godbille E. and Viennet R. (1978): Quantitative determination of vincamine in human plasma by gas chromatography-mass spectrometry. 5th Int. Symp. Mass Spectrom. Biochem. Med. (Rimini, Italy), Abstr. No. 16.

  44. Hoppen H.D., Heuer R., Seidel G. (1978): Determination of vincamine in plasma by selected ion monitoring. Biomed. Mass. Spectrom.,5, 133–138.

    Article  CAS  PubMed  Google Scholar 

  45. Buge A., Rancurel G., Bianchetti G. and Dubruc C. (1981): Comparaison des taux plasmatiques de deux formes galéniques différentes de vincamine. Psychol. Méd. (Paris),13, 183–187.

    Google Scholar 

  46. Rognoni F., Viganó V., Periti P. and Colombo P.L. (1976): Multi-compartmental modeling and kinetic parameter identification of the systemic distribution of vincamine after oral administration in the rat and in the human. Int. J. Clin. Pharmacol.,14, 231–237.

    Google Scholar 

  47. Rognoni F., Viganó V., Periti P. and Colombo P.L. (1977): Multi-compartmental modeling and kinetic parameter identification of the systemic distribution of vincamine after oral administration in the rat and in the human. Int. J. Clin. Pharmacol.,15, 373–380.

    CAS  Google Scholar 

  48. Moulin M.A., Kinsum H. and Bigot M.C. (1978): Pharmacokinetical parameters of vincamine in dogs. Eur. J. Drug Metab. Pharmacol.,3, 73–77.

    Article  CAS  Google Scholar 

  49. Bres J., Soebito S., Bressole F. and Monsoncles D. (1980). Pharmacocinétique de la vincamine chez le chien à partir des concentrations dans le sang total ou dans le plasma. Utilisation de calculateurs digitaux ou analogiques, comparaison des méthodes graphiques. Trav. Soc. Pharm. Montpellier,40, 181–216.

    CAS  Google Scholar 

  50. Soebito-Saleh S. (1980): Influence de la distribution dans les érythrocytes et de la liaison aux protéines de la vincamine sur son comportement pharmacocinétique. Thèse de 3ème cycle en pharmacocinétique et pharmacologie expérimentales et clinique. Montpellier, cited in 49.

  51. Siegers C.-P., Iven H. and Strubelt O. (1977): Plasmaspiegel und renale Ausscheidung von Vincamin nach oraler Applikation bei Probanden. Arzneim.-Forsch. (Drug. Res.),27, 1271–1274.

    CAS  Google Scholar 

  52. Siegers C.-P., Heiss W.D. and Kohlmeyer K. (1977): Plasma- und Liquorspiegel von Vincamin nach intravenöser Infusion bei Patienten. Arzneim.-Forsch. (Drug. Res.),27, 1274–1277.

    CAS  Google Scholar 

  53. Witzmann H.K., Siegers S.P., Heiss W.D. and Kohlmeyer K. (1977): Effect of vincamine on CBF under pharmacokinetic aspects. Acta Neurol. Scand.,56, Suppl. 64, 410–411.

    Google Scholar 

  54. Aztegui B.M.R. and Ramirez C.J. (1978): Niveles Sanguineos de vincamina. Estudio comparativo entre vincamina de accion prolongada y de accion immediata. Prensa Med. Mex. (Mexico),43, 61–63.

    Google Scholar 

  55. Weihgold K., Specker M. and Leuscher F. (1978): Bioverfügbarkeit und In vitro-Freisetzung von handelsüblichen Vincamin-Retard-preparaten. Therapiewoche,28, 4709–4714.

    CAS  Google Scholar 

  56. Erking W., Lücker P.W., Metz G., Specker M. und Wetzelsberger K. (1978): Relative Bioverfügbarkeit einer Vincamin-Retard-Zubereitung. Pharmakokinetische Untersuchungen und gesunden Verschuspersonen. Arzneim.-Forsch. (Drug Res.),28, 2332–2336.

    CAS  Google Scholar 

  57. Ventouras K., Boucherat J. and Buri P. (1977): Influence des facteurs technologiques sur la libération de la vincamine incorporée dans des matrices hydrophiles. Pharm. Acta Helv.,52, 119–123.

    CAS  PubMed  Google Scholar 

  58. Hinkelmann B., Bentel U., Hangleiter P., Maisenbacher J. (1979): VincaprontR Retard in der Geriatrie. Ergebnisse einer Multicentre-Studie an Patienten mit mentalen Abbauprozessen. Münch. Med. Wochenschr.,121, 1427–1428.

    CAS  Google Scholar 

  59. Bartels H. (1977): Therapie der zerebrovaskularen Insuffizienz. Doppelblindprüfung von CetalR retard gegen Cinnarizin. Münch. Med. Wochenschr.,119, 1407–1410.

    CAS  Google Scholar 

  60. Schenker H. (1979): Die medikamentöse Beeinflussung zerebraler Leistungsstörungen mit Vincamin bei alten Menschen. Ergebnisse einer Doppelblindstudie. Schweiz. Rundschau Med. (Praxis),68, 1005–1011.

    CAS  Google Scholar 

  61. Curtze A. (1978): Beziehung zwischen der In-vitro-Freisetzung und Bioverfügbarkeit von Vincamin bei CetalR retard. Therapiewoche,28, 5026–5028.

    Google Scholar 

  62. Lörincz Cs., Szász K. and Kisfaludy L. (1976): The synthesis of ethyl apovincaminate. Arzneim.-Forsch. (Drug Res.),26, 1907.

    Google Scholar 

  63. Vereczkey L., Zólyomi G. and Szporny L. (1976): Pharmacokinetic data on Tritium labelled ethyl apovincaminate. Arzneim.-Forsch. (Drug Res.),26, 1929–1933.

    CAS  Google Scholar 

  64. Vereczkey L., Tamás J. and Vajda H.J. (1976): Metabolism of Apovincaminic acid ethyl ester (RGH-4405) in rats. Advances in mass spectrometry in biochemistry and medicine. Vol. 2. (Frigerio E. ed.) Spectrum Publications, Inc. New York, 11–18.

    Google Scholar 

  65. Vereczkey L. and Szporny L. (1976): Metabolism of ethyl apovincaminate in the rat. Arzneim.-Forsch. (Drug Res.),26, 1933–1938.

    CAS  Google Scholar 

  66. Szeleczky G. and Vereczkey L. (1983): Absorption, distribution elimination and metabolism of3H-vinpocetine (CavintonR) in dogs. Symposium of the Hungarian and Polish Pharmacological Societies on Pharmacokinetics aspects of Drug research. Visegrád (Hungary) Abs. No. 26.

  67. Polgár M. and Vereczkey L. (1984): Pharmacokinetics and metabolism of vinpocetine in human. Iuphar 9th Int. Congr. Pharmacol. London, Abs. No. 495 P.

  68. Uemura I., Uda F., Ohashi H., Fujino A., Tokiwa T., Ohshima S., Sugii E., Nakayoshi H. (1982): “The metabolic fate of TCV-3B in rats”. Japanese Pharmacol. Ther.,10, 1907–1929.

    CAS  Google Scholar 

  69. Motohashi M., Yoshida K., Torii H., Tsukamoto T., Tanaya S. (1984): “Metabolism of vinpocetine (TCV-3B), a cerebral vasodilator enhancing cerebral metabolism” (in Japanese) J. Takeda Res. Lab.,43, 33–38.

    CAS  Google Scholar 

  70. Vereczkey L. and Szporny L. (1976): The absorption, excretion tissue distribution and metabolism of apovincaminic acid ethyl ester in the rat. in “Symposium on pharmacology of vinca alkaloids. (Second Congress of the Hungarian Pharmacological Society Vol. 5.) (Knoll J. and Fekete Gy. eds.) Akadémiai Kiadó, Budapest, p. 81–84.

    Google Scholar 

  71. Benakis A., Plessas Ch., Sugnaux F.R., Bouvier Cl., Reber G. and Vereczkey L. (1983): Pharmacokinetics of a new vasocilator drug, vinpocetine (CavintonR) in man. II. World conference on clinical pharmacology and therapeutics. Washington, D.C. Abstr. No. 461.

  72. Vereczkey L., Szentirmay Zs. and Szporny L. (1979): Kinetic metabolism of vinpocetine in the rat. Arzneim.-Forsch. (Drug Res.),29, 953–956.

    CAS  Google Scholar 

  73. Czira G., Vereczkey L., Tamás J. and Szporny L. (1978): Direct quantification of apovincaminic acid ethyl ester (CavintonR) in human plasma and urine by mass fragmentography. in “Recent developments in mass spectrometry in biochemistry and medicine”. Vol. 1. (Frigerio A. ed.) Plenum Press, New York and London, p. 143–151.

    Google Scholar 

  74. Polgár M. and Vereczkey L. (1983): Gas-liquid chromatographic method for quantification of vinpocetine in biological fluids, in “Chromatography in biochemistry, medicine and environmental research” Vol. 1. (Frigerio A. ed.) Elsevier Sci. Publ. Co. Amsterdam, p. 77–81.

    Google Scholar 

  75. Kozma M., Pudleiner P. and Vereczkey L. (1982): Determination of apovincaminic acid in biological samples by high-performance liquid chromatography. J. Chromatog.,241, 177–182.

    Article  CAS  Google Scholar 

  76. Polgár M. and Vereczkey L. (1982): Determination of apovincaminic acid in human plasma by gas-liquid chromatography. J. Chromatog.,241, 29–32.

    Article  Google Scholar 

  77. Vereczkey L., Czira G., Tamás J., Szentirmay Zs. and Szporny L. (1978): Comparative studies on the pharmacokinetics of Cavinton in humans and in rats. Industrial and environmental xenobiotics. In vitro versus in vivo biotransformation and toxicity (Fouts J.R. and Gut I. eds.). Excerpta Medica, Amsterdam, Oxford, p. 132–134.

    Google Scholar 

  78. Pudleiner P. and Vereczkey L. (1983): Study on the absorption of apovincaminic acid in rats and dogs. II. Int. Conf. on Drug Absorption. Edinburgh, Abs. No. 78.

  79. Polgár M. and Vereczkey L. (1984): Pharmacokinetics of vinpocetine (CavintonR) in dog. Polish J. Pharmacol. in press.

  80. Vereczkey L, Czira G., Tamás J., Szentirmai Zs., Botár Z. and Szporny L. (1979): Pharmacokinetics of vinpocetine in humans. Arzneim.-Forsch. (Drug Res.),29, 957–960.

    CAS  Google Scholar 

  81. Polgár M. and Vereczkey L. (1983): Pharmacokinetics of after intravenous, intramuscular and oral administration. RGD-27441.

  82. Polgár M., Vereczkey L. and Nyáry I. (1985): Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid in plasma and cerebrospinal fluid after intravenous infusion. Effect of the drug on the cerebral blood flow. J. Pharm. Biomed. Analysis,3, 131–139.

    Article  Google Scholar 

  83. Imamoto Tetsuji, Tanebe Masa, Fujiwara Hideshi, Shimamoto Norio and Hirata Minoru (1982): Effects of vinpocetine (TCV-3B) and apovincaminic acid (AVA) on cerebral and peripheral circulation (in Japanese) Japanese Pharmacology and Therapeutics,10, 1877–1890.

    CAS  Google Scholar 

  84. Mikio M. (1982): Efficacy and safety of long-term administration of TCV-3B tablets and examination of blood levels. Japanese. Pharmacol. Ther.,10, 1937–1944.

    Google Scholar 

  85. Kuzuya F. (1982): Pharmacokinetic study of TCV-3B (vinpocetine) in man. Japonese Pharmacol. Ther.,10, 1931–1936 (in Japonese).

    Google Scholar 

  86. Kozma M. and Vereczkey L. (1983): Pharmacokinetic investigation on apovincaminic acid after i.v., i.m. and per os administration of different Cavinton preparations. RGD-27440.

  87. Miskolczi P., Vereczkey L., Szalay L. and Göndöcs Cs. (1984): Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function. Eur. J. Drug Metab. Pharmacok.,9, 165–175.

    Google Scholar 

  88. Pudleiner P. and Vereczkey L. (1984): Pharmacokinetic invetigation of control-released Cavinton, RGD-31181.

  89. Marzo A., Quadro G., Stradi R., Saccarello M.L., Molteni L. and Bruno G. (1981): Simultaneous evaluation of apovincaminic acid esters and their metabolite apovincaminic acid by solvent partition and GLC in biological samples. Preliminary data with MR 711. Arzneim.-Forsch. (Drug Res.),31, 1681–1684.

    CAS  Google Scholar 

  90. Szporny L. and Pálosi É. (1974): “Effect of vincanol (RGH-4406) on the central nervous system”. Journal de Pharmacologie,5, Suppl. No. 2, 97–98. Collegium Internationale Neuropsychopharmacologicum IX. Paris, Abs. No. CJ7.

  91. Vereczkey L., Rosdy B. and Szporny L. (1979): Data to the pharmacokinetic study of vincanol. 3rd Congress of the Hung. Pharm. Soc. Budapest, Abs. p. 98.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacokinetics and Drug Metabolism, Chemical Works of Gedeon Richter Ltd., P.O. Box 27., H-1475, Budapest 10., Hungary

    L. Vereczkey

Authors
  1. L. Vereczkey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vereczkey, L. Pharmacokinetics and metabolism of vincamine and related compounds. European Journal of Drug Metabolism and Pharmacokinetics 10, 89–103 (1985). https://doi.org/10.1007/BF03189702

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189702

Key-words

Search

Navigation